The TGA and Research Peptides, Explained

What is the TGA's relationship to research peptides?

The Therapeutic Goods Administration (TGA) is the Australian Government body, part of the Department of Health, that regulates the safety, quality and effectiveness of therapeutic goods supplied in Australia. Research peptides sold for laboratory research use are a separate category. They are not approved therapeutic goods, they are not listed on the Australian Register of Therapeutic Goods, and they are supplied strictly as research-use-only compounds, not for human or animal use. This article explains how the TGA framework works and where research-use-only compounds sit relative to it, without making any therapeutic or dosing claims.

In short, the TGA assesses and monitors medicines and medical devices that are intended to be supplied for use in people. A laboratory research chemical that is sold for research purposes only is not presented as a medicine, is not evaluated by the TGA as a medicine, and carries no TGA approval. Understanding that distinction is the foundation of everything below.

What the TGA is and what it does

The TGA regulates the safety, quality and effectiveness of therapeutic goods in Australia. Its role spans the full life cycle of a product.

Broadly, the TGA's work includes the following areas.

• Assessing new prescription medicines, over-the-counter medicines and medical devices before they can be lawfully supplied.
• Maintaining the Australian Register of Therapeutic Goods, the official register of goods that may be supplied.
• Monitoring products already on the market for ongoing safety and quality.
• Taking compliance and enforcement action against serious or repeated breaches of the Therapeutic Goods Act.
• Regulating how therapeutic goods may be advertised to the public.

The ARTG, and what registered or listed means

The Australian Register of Therapeutic Goods (ARTG) is the TGA's electronic register of therapeutic goods that can be lawfully supplied in Australia. Most therapeutic goods, whether made locally or overseas, need to be included on it before supply, with limited exemptions such as certain compounded medicines.

The ARTG uses risk-based categories. The key terms you will see are listed and registered.

A number next to one of these codes simply tells you the product has an entry on the ARTG. Research-use-only compounds are not therapeutic goods, so they do not carry an AUST L or AUST R number.

• Listed medicines (AUST L) are lower-risk products, including many complementary medicines. The TGA checks them for safety and quality, but not for how well they work.
• Registered medicines (AUST R) are higher-risk products, including all prescription medicines. They receive a higher level of assessment, including efficacy, before registration.

The Poisons Standard and Schedule 4

Separate to the ARTG, Australia has the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). It sorts substances into schedules that set how tightly their supply is controlled. The schedule a substance sits in is a legal classification, not a statement about any particular product or brand.

Schedule 4 is the Prescription Only Medicine category. In general terms, Schedule 4 substances are those that the Poisons Standard says should be supplied on the order of an authorised prescriber and dispensed through the usual regulated channels. Advertising of prescription-only substances to the public is restricted.

How individual substances are treated in practice also depends on state and territory legislation, which can classify substances as restricted under its own poisons laws. For a definitive answer on any specific substance, the current Poisons Standard on the Federal Register of Legislation and the relevant state or territory law are the authoritative sources. We summarise this neutrally and do not provide legal advice.

Research use only versus approved therapeutic goods

A research-use-only compound is a laboratory research chemical supplied for in-vitro or scientific research purposes. It is not presented, labelled or sold as a medicine, a supplement or a product for human or animal consumption. That framing is central, because it is what separates a research chemical from a therapeutic good in the regulatory sense.

An approved therapeutic good, by contrast, has been through the TGA's assessment process for its intended use, carries an ARTG entry, and is supplied through regulated channels for that approved purpose. The two categories should not be conflated. A compound being available for research does not imply it is approved, safe or lawful for any use in people.

If you are researching the broader commercial and consumer-law context around how these compounds are described and sold in Australia, the guides below cover related ground.

ACCC rules for research peptides in Australia Research peptides in Australia: a buyer's guide

Where common research peptides sit

Many compounds studied in peptide research, including examples such as BPC-157, CJC-1295, TB-500 and GHK-Cu, are not listed on the ARTG and are not TGA-approved medicines. In other words, they have not been assessed and approved by the TGA as therapeutic goods for supply in Australia.

Some peptide substances are discussed in legal commentary as falling within prescription-only scheduling, with the practical position varying by state and territory. Because scheduling and state law can change, and because the treatment of a specific substance can be nuanced, the current Poisons Standard and the relevant jurisdiction's law remain the authoritative references. We state this neutrally rather than asserting a fixed status for any single compound.

For the legal status of one widely searched example, and for related sporting-body classifications, see the following resources.

Is BPC-157 legal in Australia? WADA banned peptides explained

Personal importation, in neutral terms

Australia operates a Personal Importation Scheme that sets out, at a high level, the limited circumstances in which individuals may import certain therapeutic goods for personal use, subject to conditions. This is a factual feature of the regulatory landscape.

We do not provide instructions on importing anything, and nothing here should be read as encouraging importation of any substance. The scheme has conditions and exclusions, and separate laws administered by the TGA and by border agencies can apply. Anyone wanting to understand their obligations should consult the TGA's own published information and, where appropriate, seek independent legal advice.

Why documentation and transparency matter

Because research-use-only compounds sit outside the ARTG approval framework, independent documentation becomes the practical way to understand what a given research item actually contains. Transparency around identity and purity is a quality-and-provenance question, not a therapeutic claim.

Two common forms of documentation in the research-chemical space are independent laboratory analysis and batch-level records that can be checked against a public register.

Third-party tested peptides in Australia How to verify a peptide batch on a public register